Revenue, 2025

USD 4.09 Billion

Forecast, 2035

USD 6.38 Billion

CAGR, 2026-2035

4.5%

Report Coverage

Global

Meningococcal Vaccines Market Trends for 2026

The global meningococcal vaccines market size was estimated at USD 4.09 billion in 2025 and is predicted to increase from USD 4.28 billion in 2026 to approximately USD 6.38 billion by 2035, expanding at a CAGR of 4.5% from 2026 to 2035.

The rise in the outbreaks of meningitis cases is increasing the adoption of the meningococcal vaccines globally. The growing R&D activities, government initiatives, technological advancements, and new vaccine launches are also enhancing the market growth.

Key Takeaways

• Meningococcal vaccines market to crossed USD 4.28 billion by 2026.
• Market projected at USD 6.38 billion by 2035.
• CAGR of 4.5% expected in between 2026 to 2035.
• North America held the major revenue share in the global meningococcal vaccines market by 56% in 2025.
• Asia Pacific is expected to be the fastest-growing region between 2026 and 2035.
• By type, the bivalent segment dominated the market by 50% in 2025 and is expected to be the fastest growing during the forecast period.
• By brand type, the Menveo segment registered its dominance over the global market by 15% in 2025.
• By brand type, the Nimenrix segment is expected to be the fastest-growing during the forecast period.
• By serotype, the Y segment held a dominant revenue share in the market by 20% in 2025.
• By serotype, the B segment is expected to be the fastest growing during the forecast period.
• By age group type, the children and adults (2 years and above) segment held a dominant position in the meningococcal vaccines market by 30% in 2025.
• By age group type, the infants (0 to 2 years) segment is expected to be the fastest growing during the forecast period.
• By sales channel type, the private segment held the major revenue share in the market by 60% in 2025 and is expected to be the fastest growing during the forecast period.

What are the Meningococcal Vaccines?

The meningococcal vaccines market is driven by rising meningococcal disease incidences, growing government immunization initiatives, and expanding technological advancements. The meningococcal vaccines encompass vaccines developed to provide protection against Neisseria meningitidis, which is a bacterium responsible for meningitis and septicaemia. These vaccines help in preventing meningitis, septicaemia, their outbreaks, and protect the high-risk population, preventing further complications.

What is the Use of AI in the Meningococcal Vaccines Market?

The use of AI in the development of meningococcal vaccines is increasing as it helps in predicting the target protein and antigen, promoting the development of optimized vaccines. It also helps in detecting adverse effects by determining the risk and offering safety monitoring, where it also provides the development of personalized vaccination strategies by identifying high risk population. It also helps in clinical trials optimization and forecasting outbreaks.

What are the Trends & Future Outlook of the Meningococcal Vaccines Market?

Increased Disease Awareness

The growing educational campaign and increasing meningitis outbreaks are increasing health awareness, driving the demand and adoption of the meningococcal vaccines, as well as promoting the development of new vaccines.

Growing Infant Immunization

Increasing vaccination programs, growing regulatory approvals of the meningococcal vaccines, and government immunization campaigns are also increasing their use to provide long term protection to the infants.

Expanding Innovation

The companies are developing various multivalent vaccines, where the growing R&D activities are also increasing the development of next-generation vaccines and new delivery systems to improve vaccine efficacy.

Executive Summary Table

Segmental Insights

By Type Insights

Why Did the Bivalent Segment Dominate in the Meningococcal Vaccines Market in 2025?

Explanaion

• Bivalent holds a 50% share in the Meningococcal Vaccines market due to its dual protection against two major serotypes, making it the preferred choice for many vaccination programs.
• Quadrivalent captures 45% of the market as it offers broader protection against four serotypes, gaining popularity in immunization campaigns for its wider coverage.
• The Others segment represents 5% of the market, consisting of specialized vaccines that are growing in niche areas due to specific regional or serotype needs.

The bivalent segment led the market by 50% in 2025 and is expected to show the highest growth over the forecast period, driven by its increased use against serotypes A and C. Growth in vaccination programs also increased its use and production rates, and its affordability also enhanced adoption rates.

By Brand Insights

How Menveo Segment Dominated the Meningococcal Vaccines Market in 2025?

Explanation

• Menveo holds a 30% share in the Meningococcal Vaccines market, dominating due to its effectiveness in offering broad protection against multiple meningococcal serotypes, making it a preferred choice in immunization programs.
• Menactra captures 15% of the market, with strong adoption in adolescent vaccination programs, but does not dominate as much compared to other brands with broader coverage.
• Nimenrix holds 25% of the market, gaining momentum for its quadrivalent protection, widely used across both children and adults in various regions.
• Trumenba has a 10% share, focusing on serotype B protection, but does not dominate due to its specialized nature in certain regions and age groups.
• Bexsero also holds 15% of the market, growing due to its specific coverage against serotype B, although it faces competition from broader vaccines like Menveo and Nimenrix.
• The Others segment represents 5% of the market, consisting of smaller or emerging brands with niche appeal in specific regions or demographics.

The Menveo segment held the largest revenue share of the market by 15% in 2025, due to its ability to target four different serotypes, that is, A, C, W, and Y. Its long-lasting immunity also increased its use, where its good tolerability and safety profile also increased its use, which promoted its production rates.

Nimenrix

The Nimenrix segment is expected to grow at the fastest CAGR during the predicted time, driven by its quadrivalent action against A, C, W, and Y serotypes. The growing immunization programs, disease outbreaks, government support, and increasing health awareness are also driving their demand.

By Serotype Insights

Which Serotype Type Segment Held the Dominating Share of the Meningococcal Vaccines Market in 2025? 

Explanation

• Serotype Y holds a 30% share in the Meningococcal Vaccines market, dominating due to its widespread presence and significant impact in ongoing meningitis outbreaks.
• Serotype B captures 25% of the market, gaining momentum with increased vaccination efforts and higher incidence rates in certain regions, particularly in adolescents and young adults.
• Serotype A has a 20% share, remaining important in regions with high meningitis prevalence, especially in parts of Africa, but does not dominate as much due to successful vaccination campaigns.
• Serotype W-135 represents 15% of the market, gaining momentum as regional outbreaks drive vaccination programs targeting this serotype.
• Serotype C accounts for 10% of the market, with its prevalence decreasing in areas with strong immunization programs, limiting its dominance.

The Y segment held the dominating share of the market by 20% in 2025, due to growth in their incidence rates, which increased the demand for their effective vaccinations. The growth in the immunization programs also recommended the use of ACWY vaccines such as Menveo and Nimenrix to control their outbreaks.

B

The B segment is expected to gain the highest share during the upcoming years, due to growing innovations of MenB vaccines and increasing disease burden. This is increasing the adoption of various meningococcal vaccines, where the growing health awareness, regulatory approvals, and vaccinations are also increasing their demand.

By Age Group Insights

What Made Children and Adults (2 years and above) the Dominant Segment in the Meningococcal Vaccines Market in 2025?

Explanation

• Children and adults (2+ years) dominate the Meningococcal Vaccines market with a 70% share, driven by widespread vaccination programs targeting school-aged children, adolescents, and young adults who are at higher risk for meningitis outbreaks.
• Infants (0 to 2 years) hold a 30% share, as they are an important group for early immunization, but the larger market share lies with older age groups due to the greater focus on preventing meningococcal disease in schools and communities.

The children and adults (2 years and above) segment contributed the biggest revenue share of the market by 30% in 2025, due to growth in the incidence of invasive meningococcal disease (IMD) in children. This increased the use of meningococcal vaccines in children and adults to reduce the outbreak risk, where these vaccinations were also supported by the government, schools, and colleges.

Infants (0 to 2 years)

The infants (0 to 2 years) segment is expected to witness the fastest growth during the upcoming years, due to their high susceptibility and growing parental awareness. This is increasing the use of various meningococcal vaccines for routine immunization to provide protection and prevention of outbreaks.

By Sales Channel Insights

Why the Private Segment Dominated the Meningococcal Vaccines Market?

Explanation

• The private segment dominates the meningococcal vaccines market with a 60% share, driven by higher demand for faster access to vaccines, more flexible administration, and the ability to cater to individuals who seek vaccines outside of public health programs.
• The public segment holds a 40% share, playing a crucial role in mass immunization campaigns, but does not dominate as much due to the limited flexibility and availability compared to private healthcare options.

The private segment accounted for the highest revenue share of the market by 60% in 2025 and is expected to expand rapidly during the upcoming years, driven by its affordability and dispensing of high-quality or branded vaccines. Moreover, the presence of a wide range of vaccines and faster access also increased their use.

Regional Insights

Growing Awareness Drives North America

North America dominated the meningococcal vaccines market by 56% in 2025, due to the growth in disease awareness, where the growth in healthcare spending also increased their production rates. The presence of the advanced healthcare sector also increased its availability, where the rise in immunization programs also contributed to the market growth.

U.S. Market Trends

The growing health campaign in the U.S. is increasing meningococcal awareness, driving the use of meningococcal vaccines. The growing insurance coverage and outbreaks of the disease are also increasing the vaccination program, promoting their use, where the growing vaccine approvals are also creating new opportunities for their advancements.

Expanding Immunization Boosts the Asia Pacific

Asia Pacific is expected to host the fastest-growing meningococcal vaccines market during the forecast period, due to expanding immunization programs and government initiatives. The rapid urbanization and increasing disease awareness are also increasing the development and adoption of meningococcal vaccines, enhancing the market growth.

India Market Trends

The expanding immunization programs in India are increasing the development and launch of new meningococcal vaccines, where the growing disease awareness is also increasing their demand. Additionally, growing healthcare investments and expanding vaccine manufacturing capabilities are also enhancing their innovations.

Europe Driven by Focus on Outbreak Preparedness

Europe is expected to grow significantly in the meningococcal vaccines market during the forecast period, due to the growing focus on outbreak preparedness and the presence of well-established companies, which are increasing the adoption of various meningococcal vaccines. Growing immunization programs are also promoting the market growth.

UK Market Trends

The growing disease awareness due to expanding immunization programs and educational campaigns across the UK are increasing the adoption of the meningococcal vaccines. The growing disease outbreaks, R&D activities, and government funding are also propelling the development of new vaccines.

Meningococcal Vaccines Market Value Chain Analysis

R&D

• The R&D of the meningococcal vaccines focuses on the development of pentavalent (MenABCWY) combination vaccines and affordable multivalent conjugate vaccines.
• Key players: GSK, Pfizer, Serum Institute of India.

Clinical Trials and Regulatory Approvals

• The safety and immunogenicity are evaluated in the clinical trials and regulatory approvals of the meningococcal vaccines.
• Key players: GSK, Pfizer, Sanofi.

Patient Support and Services

• The educational resources and financial assistance programs are provided in the patient support and services of the meningococcal vaccines.
• Key players: GSK, Pfizer, Sanofi.

Meningococcal Vaccines Market Top Vendors and Their Offerings

SWOT Analysis

Strengths

• The meningococcal vaccines offer broad protection against various serogroups such as A, B, C, W, and Y.
• These vaccines offer long-lasting immunity, which increases their use for the prevention of meningitis.
• They also offer flexible age coverage, which increases their use across various age groups.
• Additionally, their enhanced safety and tolerability are also increasing their acceptance rates.

Weaknesses

• The high cost associated with the meningococcal vaccines acts as the major weakness in the meningococcal vaccines market, limiting their accessibility.
• These vaccines require multiple doses, which reduces the patient's adherence to the treatment.

Opportunities

• The growing health awareness is increasing the adoption of the meningococcal vaccines.
• The growing immunization campaigns are also increasing their demand.
• The growing development of new and combination vaccinees are also increasing their use. 
• Growing government support and travel vaccination are also increasing their use.

Threats

• The use of sophisticated technology, a skilled workforce, and raw materials increased the production cost of the meningococcal vaccines.
• Additionally, the complex production process and regulatory challenges also limit their innovations.

What are the Recent Developments in the Meningococcal Vaccines Market?

• In April 2025, Penbraya, a combination of Trumenba targeting meningococcal group B and Nimenrix targeting meningococcal groups A, C, W-135, and Y, was announced to have received FDA approval against these five meningococcal serogroups, leading to invasive meningococcal disease (IMD), which was announced by Pfizer Inc.
• In March 2026, the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration was received by Chengdu Kanghua Biological Products Co., Ltd. for its ACYW135 group meningococcal conjugate vaccine, authorizing the launch of clinical trials against epidemic cerebrospinal meningitis/meningococcal, caused by meningococcal groups A, C, Y, and W135. 

Segments Covered in the Report

By Type 

• Bivalent
• Quadrivalent
• Others

By Brand

• Menactra
• Menveo
• Nimenrix
• Trumenba
• Bexsero
• Others 

By Serotye

• A
• B
• C
• W-135
• Y

By Age Group

• Infants (0 to 2 years)
• Children and Adults (2 years and above)

By Sales Channel

• Private
• Public

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA